Kornimate/medical-research-clean huggingface dataset:
minimizing the risk for obesity during infancy by extensive advisory service

Conditions: Reduce the Risk of Obesity During Infancy; Reduce the Risk of Insulin Resistance

Summary: 0-hypothesis: advisory support does not 1. prolong the the breast-feeding period 2. minimize the risk of obesity and metabolic dysfunction in infants of obese mothers


Eligibility criteria:
inclusion criteria: healthy, term infants informed and written consent obtained from both parents - exclusion criteria: sick infants preterm infants no consent -

Keywords: obesity, insulin resistance
comparison of face-to-face, synchronous and asynchronous use of methods tele-assessment

Conditions: Stroke Patients

Summary: the aim of the study is to examine the reliability and validity of the synchronous and asynchronous application of berg balance scale and tinetti balance test in stroke patients.

two physiotherapists will evaluate stroke patients' balance using the berg balance scale and the tinetti balance test. before the evaluation, patients will be informed about the mask, distance, and hygiene issues, which will be considered in the assessment. on the first day, information about the patient and the disease, filling in the patient data form, and face-to-face assessment will be made face to face with the patients. the next day, one synchronous and asynchronous tele-evaluation method will be applied. evaluations will be made at the same time zone of the day, determined by the randomization method, one day apart. for the learning effect to not positively impact a technique in the assessments, the order of the checks applied to each will change. the first physiotherapist will conduct face-to-face interviews and evaluations in a clinical setting. in the meantime, necessary measures will be taken due to the pandemic. the synchronous tele-assessment will be evaluated online in real-time by the second physiotherapist. at the same time, the first physiotherapist will make their evaluations online without giving instructions during this evaluation. for asynchronous tele-assessment, a reference evaluation video will be sent to the patients. relatives of the patients will be asked to watch this video, make the evaluation and take a video recording at the same time. then, these video recordings will be evaluated separately by the first and second physiotherapists, and the results will be compared. each assessment will take approximately 30 minutes. the test evaluation will be performed again. asynchronous tele-evaluation videos will also be re-evaluated in 25% of individuals after ten days. this way, instead of having the patients repeat the same tests, the test will be repeated on the first test.

Eligibility criteria:
inclusion criteria: * have been diagnosed with stroke, * aged 18 and over, * literate, * stroke caused by anterior circulation, * computer, phone and tablet etc. having experience in the use of technological devices and experienced caregivers in this regard, * at least stage 3 in the lower extremities according to brunnstrom recovery stages, * a score of 24 and above in the mini mental state test exclusion criteria: * vestibular lesion/dysfunction, * auditory and visual lesion/dysfunction, * accompanying neurological disorders (multiple sclerosis, parkinson, ataxia, dystonia, dyskinesia, etc.) * psychiatric disorders * patients with aphasia to a degree that causes communication problems will not be included.

Keywords: stroke balance synchronous tele-assessment asynchronous tele-assessment
diclofenac 25mg/paracetamol 500 mg and diclofenac 50 mg/paracetamol 500 mg for patients with pain

Conditions: Pain

Summary: the purpose of this study is to collect adverse events and identify risk factors in patients that are taking dolocordralan extra 25® and dolocordralan extra forte®


Eligibility criteria:
inclusion criteria: * patients who are prescribed dolocordralan extra 25 and dolocordralan extra forte at any of the participating clinics * patients who sign the informed consent form * patients who agree to comply with the study procedures exclusion criteria: * please see the protocol for further information on exclusion criteria
the efficacy of intensive nutritional supplement in patient with stroke

Conditions: Stroke; Malnutrition

Summary: the aim of this prospective randomized controlled study is to demonstrate the efficacy of intensive nutritional supplement in patient with stroke.

elderly patients, including those who have had a stroke, are more at risk of undernutrition than other groups because of reduced nutritional reserves, prolonged hospital stay and increased demands of repeated ill-health. stroke may compound these problems because of physical and mental incapacity, problems with perception and communication, and swallowing disorders. the full extent of undernutrition and its independent contribution to stroke outcome is not presently known. it is also not known whether it can be corrected, and whether doing so would improve the outcome. the aim of this study is therefore to describe the efficacy of intensive nutritional supplement in patient with stroke.

Eligibility criteria:
inclusion criteria: * 1 st onset stroke patient * mri confirms his/her stroke * more than 2.5% weight los within 2 weeks * initial serum albumin \< 35 g/l * bmi \< 18.5 * more than mmse 10 * medically stable exclusion criteria: * recurrent stroke patient * malabsorption patient * terminal cancer

Keywords: stroke malnutrition high protein
the comparison of pilates with cognitive functional therapy in adults with chronic neck pain

Conditions: Chronic Neck Pain

Summary: the aim of this study is to compare the effectiveness of pilates compared with cognitive functional therapy in adults with chronic neck pain.

firstly, people being informed about the study and those who determine eligibility criteria they written informer consent. after this, the participants will be randomized by a single-blind assessor in a 1:1 ration to pilates exercises and cognitive functional therapy. the participants of both groups will receive therapy twice a week for eight weeks.

Eligibility criteria:
inclusion criteria: * age 18-64 * pain in neck area for more than 3 months * pain in nprs more than 40/100 * independently mobility (with or without aid), to be capable of participating in a rehabilitation program twice a week exclusion criteria: * serious psychological pathology * recently surgery on shoulder or neck area (\<6 months) * pain relieving procedures such as injection based therapy and day case procedures (e.g. rhizotomy) in the last 3 months * pregnancy * rheumatologic/inflammatory disease (e.g. rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, lupus, scheuermann's disease) * progressive neurological disease (e.g. multiple sclerosis, parkinson's disease, motor neuron disease) * unstable cardiac conditions * red flags disorders (malignancy/cancer, acute traumas like fracture (\<6 months ago) or infection, spinal cord compression/cauda equina)
study of the pas-port® proximal anastomosis system in coronary bypass surgery

Conditions: Coronary Artery Disease

Summary: the study has been designed to comparatively evaluate the safety and effectiveness of the pas-port proximal anastomosis system and conventional suturing techniques for creation of the connection between graft veins and the aorta in patients undergoing coronary artery bypass graft surgery for treatment of coronary artery disease. patients in the study will have a coronary angiogram approximately 9 months following surgery to determine the patency of vein grafts created using either the automated pas-port or hand sewn methods. safety will be evaluated by documenting the occurence of adverse clinical events and evealuating possible association with either method.


Eligibility criteria:
pre-operatively inclusion criteria: * able to give informed consent, able to understand the intent and clinical meaning of the study as well as its implications. patient is legally competent. * assessment that the patient is willing and able to have follow-up visits and examinations * age greater than or equal to 50 years and less than 85 years * ejection fraction of \>30% * can tolerate radiographic contrast media * requires non-emergent coronary artery bypass with at least two vein bypass grafts intended * coronary artery targets intended for bypass index grafts must have \>70% native stenosis * life expectancy \>1 year exclusion criteria: * patient is participating in other clinical trials that would conflict with this protocol * unable to meet study requirements (travel, general health) * pregnancy * previous cardiac surgery * requiring preoperative use of an intraaortic balloon pump * congestive heart failure / nyha class iv * history of thromboembolic disease requiring ongoing anticoagulation therapy or the presence of a bleeding disorder * acute or chronic dialysis * creatinine of greater than 200 µmol/l (2.3 mg/dl) in the last 30 days * documented acute or suspected systemic infection * need for ongoing immunosuppressive therapy * recent (less than 2 weeks) history of cerebrovascular accident * aspirin allergy or other contraindications to aspirin use intra-operatively inclusion criteria: * patient is hemodynamically stable * open chest reassessment of the revascularization strategy confirms that two vein bypass grafts are still intended * target vessel wall properties that are suitable for performing both a hand-sewn and a pas-port anastomosis * target vessel is greater than 1.8 mm in diameter at sites where anastomoses are planned * target vessel at sites where anastomoses will be placed are free from severe calcifications or severe atheromas * the length of the vein graft(s) is adequate for both of the planned index graft revascularization strategies * vein outside diameter and double wall thickness are between 4 and 6 mm(inclusive) and less than or equal to 1.4 mm, respectively, at the graft site intended for the pas-port proximal anastomosis * the vein(s) is of suitable quality to be used as a bypass graft conduit exclusion criteria: -any of the intra-operative inclusion criteria not met
zd4054 (zibotentan) in pain-free or mildly symptomatic patients with prostate cancer and bone metastases who have rising serum prostate specific antigen (psa)

Conditions: Prostate Cancer

Summary: this study is being carried out to see if zd4054 (zibotentan) is effective in treating prostate cancer and spread of cancer to the bone, and if so, how it compares with placebo (sugar pill). the study will also provide further information on the safety of zd4054 (zibotentan).


Eligibility criteria:
inclusion criteria: * surgically or medically castrated * bone metastasis * rising psa exclusion criteria: * opiate use * prior chemotherapy

Keywords: rising psa bone metastases clinical study pain-free or mildly symptomatic
the effect of whole body cryotherapy on recovery and performance: a randomized controlled trial

Conditions: Cold

Summary: this study investigates the effects of whole-body cryotherapy vs. cold-water immersion after a muscle damage protocol.

in this study the effects of a single- or multiple whole body cryotherapy (-135°c for max. 2 minutes) vs. cold water immersion (10°c for 15 min) and a passive control group (20 min supine position) are compared. these effects are examined after a muscle damage protocol of the frontal thighs (3 x 30 jumps). the objective recovery parameters are vertical jump, maximum voluntary contraction of the anterior thigh muscle, heart rate, blood pressure, skin-core body temperature and the oxygen saturation of the thigh muscles. subjective recovery parameters are the local muscle soreness details and the general exhaustion details. the parameters are directly and 24, 48 and measured 72 hours after exposure. the aim is to elicit the effects of whole body cooling to make recommendations to. the current scientific knowledge situation calls for further studies to whole body cooling.

Eligibility criteria:
inclusion criteria: only healthy young subjects 18-35 years no musculoskeletal surgery in trunk and lower extremities injury history in trunk and lower extremity for more than one year subjects taking anticonceptive medication are allowed to participate exclusion criteria: actual injuries or injuries for less than one year in trunk and /or lower extremities injury history in trunk and lower extremity for more than one year with complaints anxiety of cooling subjects on medication pace maker cardiovascular disease pregnancy skeletal problems appendectomy for less than two years morbus raynaud syndrome

Keywords: cold recovery
efficacy and safety of activated recombinant human factor vii in treatment of bleeding in patients following hematopoietic stem cell transplantation

Conditions: Acquired Bleeding Disorder; Bleeding During/Following Surgery

Summary: this trial is conducted in the united states of america (usa). the aim of this trial is to evaluate the efficacy of activated recombinant human factor vii in treatment of bleeding in patients having undergone a hematopoietic stem cell transplantation.


Eligibility criteria:
inclusion criteria: * patients who have undergone a hematopoietic stem cell transplantation exclusion criteria: * known or suspected allergy to trial product * participation in other trials with unapproved drugs or trials with equal or similar objective
cities for better health childhood obesity prevention initiative

Conditions: Obesity

Summary: this research project is part of the 'cities for better health childhood obesity prevention initiative' (cbh copi), which aims to understand how interventions designed to improve diet and physical activity can impact children's health.


Eligibility criteria:
inclusion criteria: * informed consent obtained by the child's parent or legal guardian before any study-related activities (where study-related activities are defined as any procedure related to recording of data according to the protocol). the specific consent form and procedures for obtaining consent will be outlined by the local project partner. * aged 6-13 years (both 6 and 13 allowed) at the time of signing consent. deviations from or exceptions to this procedure must be agreed between the research team in the relevant country and the gip, and are subject to the relevant local ethical amendment procedure. the exception must be due to a scientifically sound rationale and must further consider the following guiding principles: "it must be measurable, it must have marginal utility, it must be meaningful (i.e. linked to the ultimate impact and the primary and/or secondary objective)". exclusion criteria: - children will be excluded from the study if their parent(s) do not provide fully informed consent for their data to be collected, if during the measurement day they do not agree to participate, or if the child's parent(s) or legal guardian(s) withdraw their consent for their child participating in the research at any point in line with processes described in local informed consent forms. in communications asking for consent, parents will be prompted to evaluate whether their children have issues with mental incapacity or language barriers that would preclude adequate understanding or cooperation.
clinical effectiveness and safety of amphotericin b with flucytosine-fluconazole therapy for cryptococcal meningitis

Conditions: Cryptococcal Meningitis

Summary: to study the clinical effectiveness and safety of amphotericin b with flucytosine-fluconazole therapy for cryptococcal meningitis in patients with hiv infection.

cryptococcal meningitis is an aids-defining illness mostly caused by the fungus, cryptococcus neoformans. in high-income countries, the use of amphotericin b in combination with a more expensive drug, flucytosine, is most effective for the management of cryptococcal meningitis; but access to flucytosine is severely limited in middle and low-income countries. in myanmar, currently recommended regimen for cryptococcal meningitis are combination of amphotericin b with fluconazole. although amphotericin plus flucytosine followed by fluconazole therapy is the currently preferred regimen in who treatment guidelines, it is not still commonly used in myanmar clinical practice because of its limited availability. therefore, the data regarding tolerability and clinical effectiveness of flucytosine are unavailable for myanmar patients. although trials were carried out for investigating the effectiveness of flucytosine in the hiv population of africa, the variability in drug response can occur in myanmar patients due to the racial and genetic differences and whether it is effective and safe for myanmar people is a great curiosity question for clinicians and healthcare workers. in myanmar, amphotericin plus flucytosine followed by fluconazole regimen will be supplied by national aids program (nap) and indicated in 2020. thus, the documents for effectiveness and safety profile need to be established. this is the reason that the effectiveness and safety of amphotericin b with flucytosine and fluconazole combination therapy should be studied. from this study, it can provide information to physicians regarding the effectiveness as well as safety of those drugs in the management of cryptococcal meningitis in hiv patients.

Eligibility criteria:
inclusion criteria: 1. patients with hiv-associated cryptococcal meningitis, admitted to inpatient department of shw, shm, sht, ygh, nogth and igh during the study period 2. patients of both sexes 3. age above 14 years 4. patients or caregivers who will give informed consent to participate in this study
a prospective, multi-center, observational study for signal-c test evaluation

Conditions: Colorectal Cancer; Advanced Adenocarcinoma

Summary: to evaluate the performance characteristics of signal-c™ a plasma circulating free-dna test, to detect colorectal cancer and advanced precancerous lesions (apl) in an average risk screening population for 45 and over.


Eligibility criteria:
inclusion criteria: 1. subjects aged 45-84 years at time of consent 2. intended to undergo a standard-of-care screening colonoscopy 3. considered by a physician or healthcare provider as being of 'average risk' for crc 4. willing to consent to blood draw prior to bowel preparatory procedures or undergoing colonoscopy ideally within 90 days of the date of the investigational blood draw. 5. willing to consent to follow-up for one year as per protocol 6. able and willing to sign informed consent exclusion criteria: 1. undergoing colonoscopy for investigation of crc risk symptoms 2. has undergone colonoscopy within preceding 9 years 3. positive fit/fobt result within the previous 12 months (+/- 3 months) 4. has completed cologuard or epi procolon testing within the previous 3 years. 5. has undergone a ct colonography in the prior 4 years. 6. history of colorectal cancer. 7. history of any malignancy within prior 5 years. (patients with clear clinical evidence and documentation of being cancer free and patients who have undergone surgical removal of skin squamous cell cancer may be enrolled provided the procedure was completed at least 12 months prior to the date of provision of informed consent for the study.) 8. known diagnosis of inflammatory bowel disease (ibd), including chronic ulcerative colitis (cuc) and crohn's disease (cd). 9. positive family history of colorectal cancer, defined as having a first- degree relative (parent, sibling, or child) with crc diagnosed at age \<60 years or with more than one first-degree relative diagnosed with crc at any age. 10. known hereditary/germline risk of colorectal cancer (for example, lynch syndrome or hereditary non-polyposis crc \[hnpcc\], or familial adenomatous polyposis \[fap\]). 11. any major physical trauma (e.g., disruption of tissue, surgery, organ transplant, blood product transfusion) within the 30 days leading up to the provision of informed consent. 12. known medical condition which, in the opinion of the investigator, should preclude enrollment into the study. 13. known pregnancy at informed consent, blood sample collection, and during study participation. 14. participation in a clinical research study in which an experimental medication has been administered or may be administered within the 30 days leading up to providing informed consent or may be administered through the time of colonoscopy.

Keywords: advanced precancerous lesions
autologous tumor-infiltrating lymphocyte (gt307 injection ) for treatment of patients with solid tumours

Conditions: Solid Tumor, Adult

Summary: this study is a single arm, open design aimed at evaluating the safety and tolerability of autologous tumor-infiltrating lymphocyte (gt307 injection ) for treatment of patients with solid tumours,while evaluating pharmacokinetic characteristics and efficacy assessment to determine the optimal biological dose (obd).


Eligibility criteria:
inclusion criteria: * 1. voluntarily join the study, signed informed consent form,, willing and able to comply with the study protocol; * 2. age 18 to 70 years old; * 3. patients with advanced solid tumours who have been diagnosed with: failure of standard treatment, no standard treatment, or inaccessible to standard treatment; * 4. eastern cooperative oncology group (ecog) performance status score of 0 or 1; * 5. expected survival time of ≥ 12 weeks; * 6. good function of vital organs; * 7. subjects entering this study due to disease progression must have an imaging record of disease progression before tumor sampling; * 8. at least one measurable target lesion that meets the definition of recist v1.1 after tumor sampling. exclusion criteria: * 1.patients with uncontrollable tumor-related pain as judged by the investigator; participants requiring analgesic medication must already have a stable analgesic regimen at the time of study entry; symptomatic lesions suitable for palliative radiotherapy should be completed prior to study entry; * 2.known mental illness, alcoholism, drug use or substance abuse; * 3.pregnant or lactating women; or women who are pregnant, breastfeeding, or planning to become pregnant within 1 year after cell infusion; * 4.those who have received other clinical trial drug treatment within 4 weeks before preconditioning by lymphodepletion,plan to participate in other clinical trial drug treatment during the study; * 5.the investigators determine that other conditions that make the patient not suitable for enrollment
evaluation of a smartphone-based screening tool (picterus jaundice pro) for neonatal jaundice in dark skin newborns

Conditions: Jaundice, Neonatal

Summary: a cross-sectional study at the södersjukehuset facility (stockholm, sweden) collect data of newborns from a population with neomar scale type 4 to adjust the algorithm of picterus jp

to adjust picterus jp to work in newborns with more pigmented skin, the investigators will collect a data set at sachsska barnsjukhuset södersjukhuset, stockholm sweden from 150 newborns with dark skins using picterus jp, tcb, skin measurements from a spectrometer, visual assessment, and total serum bilirubin (tsb) levels. as a control, newborns with neomar scale 1-3 will be included.

Eligibility criteria:
inclusion criteria: * infants born with gestational age ≥ 37 * birth weight ≥ 2500g * age 1 - 14 days * will have a blood sample performed, either for clinically suspected jaundice or newborn screening sample exclusion criteria: * infants showing signs of inborn disease * infants transferred to pediatric ward for treatment * infants that have received phototherapy